Functionalized triazines as potent HCV entry inhibitors.
Identifieur interne : 000B64 ( PubMed/Corpus ); précédent : 000B63; suivant : 000B65Functionalized triazines as potent HCV entry inhibitors.
Auteurs : Eric S. Mull ; Li-Qiang Sun ; Qian Zhao ; Betsy Eggers ; Kevin Pokornowski ; Guangzhi Zhai ; Ramkumar Rajamani ; Susan Jenkins ; Melissa Kramer ; Ying-Kai Wang ; Hua Fang ; Daniel Tenney ; Carl J. Baldick ; Mark I. Cockett ; Nicholas A. Meanwell ; Paul M. ScolaSource :
- Bioorganic & medicinal chemistry letters [ 1464-3405 ] ; 2017.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (chemistry), Antiviral Agents (pharmacokinetics), Antiviral Agents (pharmacology), Hepacivirus (drug effects), Hepacivirus (physiology), Humans, Membrane Fusion (drug effects), Rats, Structure-Activity Relationship, Triazines (chemistry), Triazines (pharmacokinetics), Triazines (pharmacology).
- MESH :
- chemical , chemistry : Antiviral Agents, Triazines.
- chemical , pharmacokinetics : Antiviral Agents, Triazines.
- chemical , pharmacology : Antiviral Agents, Triazines.
- drug effects : Hepacivirus, Membrane Fusion.
- physiology : Hepacivirus.
- Animals, Humans, Rats, Structure-Activity Relationship.
Abstract
A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC50 values in the HCV pseudotype particle (HCVpp) assay.
DOI: 10.1016/j.bmcl.2016.12.038
PubMed: 28089701
Links to Exploration step
pubmed:28089701Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Functionalized triazines as potent HCV entry inhibitors.</title><author><name sortKey="Mull, Eric S" sort="Mull, Eric S" uniqKey="Mull E" first="Eric S" last="Mull">Eric S. Mull</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: eric_mull@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sun, Li Qiang" sort="Sun, Li Qiang" uniqKey="Sun L" first="Li-Qiang" last="Sun">Li-Qiang Sun</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Qian" sort="Zhao, Qian" uniqKey="Zhao Q" first="Qian" last="Zhao">Qian Zhao</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Eggers, Betsy" sort="Eggers, Betsy" uniqKey="Eggers B" first="Betsy" last="Eggers">Betsy Eggers</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Pokornowski, Kevin" sort="Pokornowski, Kevin" uniqKey="Pokornowski K" first="Kevin" last="Pokornowski">Kevin Pokornowski</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Zhai, Guangzhi" sort="Zhai, Guangzhi" uniqKey="Zhai G" first="Guangzhi" last="Zhai">Guangzhi Zhai</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Rajamani, Ramkumar" sort="Rajamani, Ramkumar" uniqKey="Rajamani R" first="Ramkumar" last="Rajamani">Ramkumar Rajamani</name><affiliation><nlm:affiliation>Department of Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Jenkins, Susan" sort="Jenkins, Susan" uniqKey="Jenkins S" first="Susan" last="Jenkins">Susan Jenkins</name><affiliation><nlm:affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Kramer, Melissa" sort="Kramer, Melissa" uniqKey="Kramer M" first="Melissa" last="Kramer">Melissa Kramer</name><affiliation><nlm:affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Ying Kai" sort="Wang, Ying Kai" uniqKey="Wang Y" first="Ying-Kai" last="Wang">Ying-Kai Wang</name><affiliation><nlm:affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Fang, Hua" sort="Fang, Hua" uniqKey="Fang H" first="Hua" last="Fang">Hua Fang</name><affiliation><nlm:affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Tenney, Daniel" sort="Tenney, Daniel" uniqKey="Tenney D" first="Daniel" last="Tenney">Daniel Tenney</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Baldick, Carl J" sort="Baldick, Carl J" uniqKey="Baldick C" first="Carl J" last="Baldick">Carl J. Baldick</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Cockett, Mark I" sort="Cockett, Mark I" uniqKey="Cockett M" first="Mark I" last="Cockett">Mark I. Cockett</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Meanwell, Nicholas A" sort="Meanwell, Nicholas A" uniqKey="Meanwell N" first="Nicholas A" last="Meanwell">Nicholas A. Meanwell</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Scola, Paul M" sort="Scola, Paul M" uniqKey="Scola P" first="Paul M" last="Scola">Paul M. Scola</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28089701</idno><idno type="pmid">28089701</idno><idno type="doi">10.1016/j.bmcl.2016.12.038</idno><idno type="wicri:Area/PubMed/Corpus">000B64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Functionalized triazines as potent HCV entry inhibitors.</title><author><name sortKey="Mull, Eric S" sort="Mull, Eric S" uniqKey="Mull E" first="Eric S" last="Mull">Eric S. Mull</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: eric_mull@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sun, Li Qiang" sort="Sun, Li Qiang" uniqKey="Sun L" first="Li-Qiang" last="Sun">Li-Qiang Sun</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Qian" sort="Zhao, Qian" uniqKey="Zhao Q" first="Qian" last="Zhao">Qian Zhao</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Eggers, Betsy" sort="Eggers, Betsy" uniqKey="Eggers B" first="Betsy" last="Eggers">Betsy Eggers</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Pokornowski, Kevin" sort="Pokornowski, Kevin" uniqKey="Pokornowski K" first="Kevin" last="Pokornowski">Kevin Pokornowski</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Zhai, Guangzhi" sort="Zhai, Guangzhi" uniqKey="Zhai G" first="Guangzhi" last="Zhai">Guangzhi Zhai</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Rajamani, Ramkumar" sort="Rajamani, Ramkumar" uniqKey="Rajamani R" first="Ramkumar" last="Rajamani">Ramkumar Rajamani</name><affiliation><nlm:affiliation>Department of Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Jenkins, Susan" sort="Jenkins, Susan" uniqKey="Jenkins S" first="Susan" last="Jenkins">Susan Jenkins</name><affiliation><nlm:affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Kramer, Melissa" sort="Kramer, Melissa" uniqKey="Kramer M" first="Melissa" last="Kramer">Melissa Kramer</name><affiliation><nlm:affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Ying Kai" sort="Wang, Ying Kai" uniqKey="Wang Y" first="Ying-Kai" last="Wang">Ying-Kai Wang</name><affiliation><nlm:affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Fang, Hua" sort="Fang, Hua" uniqKey="Fang H" first="Hua" last="Fang">Hua Fang</name><affiliation><nlm:affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Tenney, Daniel" sort="Tenney, Daniel" uniqKey="Tenney D" first="Daniel" last="Tenney">Daniel Tenney</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Baldick, Carl J" sort="Baldick, Carl J" uniqKey="Baldick C" first="Carl J" last="Baldick">Carl J. Baldick</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Cockett, Mark I" sort="Cockett, Mark I" uniqKey="Cockett M" first="Mark I" last="Cockett">Mark I. Cockett</name><affiliation><nlm:affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Meanwell, Nicholas A" sort="Meanwell, Nicholas A" uniqKey="Meanwell N" first="Nicholas A" last="Meanwell">Nicholas A. Meanwell</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Scola, Paul M" sort="Scola, Paul M" uniqKey="Scola P" first="Paul M" last="Scola">Paul M. Scola</name><affiliation><nlm:affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Bioorganic & medicinal chemistry letters</title><idno type="eISSN">1464-3405</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacokinetics)</term><term>Antiviral Agents (pharmacology)</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (physiology)</term><term>Humans</term><term>Membrane Fusion (drug effects)</term><term>Rats</term><term>Structure-Activity Relationship</term><term>Triazines (chemistry)</term><term>Triazines (pharmacokinetics)</term><term>Triazines (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Triazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term><term>Triazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Triazines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term><term>Membrane Fusion</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Rats</term><term>Structure-Activity Relationship</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC<sub>50</sub> values in the HCV pseudotype particle (HCVpp) assay.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28089701</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3405</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>02</Month><Day>15</Day></PubDate></JournalIssue><Title>Bioorganic & medicinal chemistry letters</Title><ISOAbbreviation>Bioorg. Med. Chem. Lett.</ISOAbbreviation></Journal><ArticleTitle>Functionalized triazines as potent HCV entry inhibitors.</ArticleTitle><Pagination><MedlinePgn>1089-1093</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0960-894X(16)31304-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2016.12.038</ELocationID><Abstract><AbstractText>A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC<sub>50</sub> values in the HCV pseudotype particle (HCVpp) assay.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mull</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: eric_mull@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Li-Qiang</ForeName><Initials>LQ</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggers</LastName><ForeName>Betsy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pokornowski</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Guangzhi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajamani</LastName><ForeName>Ramkumar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying-Kai</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenney</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldick</LastName><ForeName>Carl J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cockett</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meanwell</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scola</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem Lett</MedlineTA><NlmUniqueID>9107377</NlmUniqueID><ISSNLinking>0960-894X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Acyl sulfonamide</Keyword><Keyword MajorTopicYN="Y">Entry inhibitor</Keyword><Keyword MajorTopicYN="Y">Hepatitis C virus</Keyword><Keyword MajorTopicYN="Y">Triazine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28089701</ArticleId><ArticleId IdType="pii">S0960-894X(16)31304-X</ArticleId><ArticleId IdType="doi">10.1016/j.bmcl.2016.12.038</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000B64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28089701
|texte= Functionalized triazines as potent HCV entry inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28089701" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |